Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2013.05.001
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Tumor Tissue microRNA Expression in Association With Triple-Negative Breast Cancer Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Expression of Androgen Receptor and C-Kit (CD117) in Triple Negative Breast Cancer

Immunopathology, Allergology, Infectology
2016English

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

Dicer Expression in Estrogen Receptor–positive Versus Triple-Negative Breast Cancer: An Antibody Comparison

Human Pathology
Forensic MedicinePathology
2016English

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

MicroRNAs Expression in Triple Negative vs Non Triple Negative Breast Cancer in Tunisia: Interaction With Clinical Outcome

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy